MXPA05009242A - Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5. - Google Patents

Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5.

Info

Publication number
MXPA05009242A
MXPA05009242A MXPA05009242A MXPA05009242A MXPA05009242A MX PA05009242 A MXPA05009242 A MX PA05009242A MX PA05009242 A MXPA05009242 A MX PA05009242A MX PA05009242 A MXPA05009242 A MX PA05009242A MX PA05009242 A MXPA05009242 A MX PA05009242A
Authority
MX
Mexico
Prior art keywords
diabetes
type
treatment
pde5 inhibitors
substantial
Prior art date
Application number
MXPA05009242A
Other languages
English (en)
Inventor
Earl Michael Gibbs
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA05009242A publication Critical patent/MXPA05009242A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El uso de un inhibidor de la PDE5 sin actividad inhibidora sustancial de la PDE2, o una sal farmaceuticamente aceptable del mismo en la preparacion de un medicamento para el tratamiento de la diabetes tipo 1. Un procedimiento de tratamiento de la diabetes de tipo 1 en un individuo que padece la diabetes de tipo 1, cuyo procedimiento comprende la administracion a dicho individuo de una cantidad eficaz de un inhibidor de la PDE5 sin actividad inhibidora sustancial de la PDE2, o un a sal farmaceuticamente aceptable del mismo.
MXPA05009242A 2003-03-17 2004-03-04 Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5. MXPA05009242A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45527703P 2003-03-17 2003-03-17
PCT/IB2004/000696 WO2004082667A1 (en) 2003-03-17 2004-03-04 Treatment of type 1 diabetes with pde5 inhibitors

Publications (1)

Publication Number Publication Date
MXPA05009242A true MXPA05009242A (es) 2006-04-18

Family

ID=33029981

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009242A MXPA05009242A (es) 2003-03-17 2004-03-04 Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5.

Country Status (7)

Country Link
EP (1) EP1605925A1 (es)
JP (1) JP2006520777A (es)
BR (1) BRPI0408500A (es)
CA (1) CA2519357A1 (es)
MX (1) MXPA05009242A (es)
TW (1) TW200503666A (es)
WO (1) WO2004082667A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563693C (en) * 2004-04-19 2010-07-06 Loma Linda University Composition and method of decreasing renal ischemic damage
EP1909793A2 (de) * 2005-07-15 2008-04-16 Proxomed Medizintechnik GmbH Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von erkrankungen oder gesundheitsstörungen, sowie abgabesysteme für dieselben
RU2008108078A (ru) * 2005-08-04 2009-09-10 Трансформ Фармасьютикалз, Инк. (Us) Новые препаративные формы, включающие фенофибрат и статин, и соответствующие способы лечения
NZ574710A (en) 2006-09-07 2012-02-24 Nycomed Gmbh Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus
CA2690004C (en) 2007-06-04 2018-01-23 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
US9943517B2 (en) * 2012-11-13 2018-04-17 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
ES2955693T3 (es) 2012-12-24 2023-12-05 Neurogastrx Inc Métodos para el tratamiento de trastornos del tracto GI
KR20160094956A (ko) 2013-11-05 2016-08-10 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 당뇨병 및 당뇨병으로부터 발생하는 합병증 질환의 치료를 위한 화합물
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
MX2017016930A (es) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526608A (ja) * 1998-10-15 2003-09-09 バイオイメージ エイ／エス 再分布及び／又は標的化での干渉によって得られる特異的治療の介入
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
DE19944161A1 (de) * 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
JP2004511433A (ja) * 2000-06-30 2004-04-15 ファイザー・インク 末梢血管疾患、末梢ニューロパシー、及び自律性ニューロパシーの処置方法
HUP0300725A3 (en) * 2000-08-11 2005-11-28 Pfizer Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
BR0206847A (pt) * 2001-02-02 2004-02-25 Pfizer Tratamento do diabete melito
BR0208078A (pt) * 2001-03-16 2004-03-02 Pfizer Compostos pirazol[4,3-d]pirimidinona como inibidores de cgmp pde
GB0106631D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
US6479493B1 (en) * 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations

Also Published As

Publication number Publication date
EP1605925A1 (en) 2005-12-21
CA2519357A1 (en) 2004-09-30
JP2006520777A (ja) 2006-09-14
BRPI0408500A (pt) 2006-03-07
WO2004082667A1 (en) 2004-09-30
TW200503666A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
IN2005KO00312A (es)
TW200639159A (en) Treatment of pain
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
TW200616644A (en) Medicine for prevention or treatment of diabetes
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
IL151628A0 (en) Combination therapies with vascular damaging activity
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
TW200503676A (en) Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
EP1695969A4 (en) ALPHA-AMINO-ACID DERIVATIVES AND THEIR USE AS MEDICINE
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
TW200642688A (en) New use of PDE7 inhibitors
MXPA05004920A (es) Combinacion que comprende un inhibidor cdk y cisplatin.
GB0313386D0 (en) Treatment of disease
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
TW200610524A (en) Medicine for prevention or treatment of diabetes
TW200608965A (en) Medicine for prevention or treatment of diabetes
BRPI0407574A (pt) combinações farmacêuticas que compreendem um inibidor de nos e um antagonista de receptor de nmda

Legal Events

Date Code Title Description
FA Abandonment or withdrawal